Single/Multiple cycles
Compared with an active control regimen, the regimen with EMEND provided superior and sustained efficacy in highly emetogenic chemotherapy
More patients on the regimen with EMEND remained free of vomiting on Days 1 through 5 as compared with those on an active-control regimen (P<0.001).
- A second trial (N=524) showed similar results.
- See single-cycle results for patients on moderately emetogenic chemotherapy
The efficacy of the regimen with EMEND was maintained through the 6 cycles of
chemotherapy studied
- A second trial showed similar results.
- See multiple-cycle results for patients on moderately emetogenic chemotherapy
Important Safety Information
EMEND and EMEND for Injection, in combination with other antiemetic agents, are indicated in adults for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
EMEND and EMEND for Injection have not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND or EMEND for Injection is not recommended.
Selected Important Safety Information
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
PRIVACY POLICY